New quinoxalin-1,3,4-oxadiazole derivatives: Synthesis, characterization, in vitro biological evaluations, and molecular modeling studies

dc.contributor.authorMirzazadeh, Roghieh
dc.contributor.authorAsgari, Mohammad S.
dc.contributor.authorBarzegari, Ebrahim
dc.contributor.authorPedrood, Keyvan
dc.contributor.authorMohammadi-Khanaposhtani, Maryam
dc.contributor.authorSherafati, Maedeh
dc.contributor.authorLarijani, Bagher
dc.date.accessioned2025-10-18T13:23:12Z
dc.date.created2021
dc.date.issued2021
dc.departmentBartın Üniversitesi
dc.description.abstractA new series of quinoxalin-1,3,4-oxadiazole (10a-l) derivatives was synthesized and evaluated against some metabolic enzymes including human carbonic anhydrase (hCA) isoenzymes I and II (carbonic anhydrases I and II), cholinesterase (acetylcholinesterase and butyrylcholinesterase), and alpha-glucosidase. Obtained data revealed that all the synthesized compounds were more potent as compared with the used standard inhibitors against studied target enzymes. Among the synthesized compounds, 4-fluoro derivative (10f) against hCA I, 4-chloro derivative (10i) against hCA II, 3-fluoro derivative (10e) against acetylcholinesterase and butyrylcholinesterase, and 3-bromo derivative (10k) against alpha-glucosidase were the most potent compounds with inhibitory activity around 1.8- to 7.37-fold better than standard inhibitors. Furthermore, docking studies of these compounds were performed at the active site of their target enzymes.
dc.identifier.doi10.1002/ardp.202000471
dc.identifier.issn0365-6233
dc.identifier.issn1521-4184
dc.identifier.issue9
dc.identifier.orcidGulcin, ilhami/0000-0001-5993-1668
dc.identifier.orcidPedrood, Keyvan/0000-0001-6759-9458
dc.identifier.orcidBarzegari, Ebrahim/0000-0002-4412-6129
dc.identifier.orcidAsgari, Mohammad Sadegh/0009-0000-9977-7044
dc.identifier.orcidTaslimi, Parham/0000-0002-3171-0633
dc.identifier.orcidLarijani, Bagher/0000-0001-5386-7597
dc.identifier.orcidUc, Eda Mehtap/0000-0002-9259-5704;
dc.identifier.pmid33999440
dc.identifier.scopus2-s2.0-85105800867
dc.identifier.scopusqualityQ2
dc.identifier.urihttps://doi.org/10.1002/ardp.202000471
dc.identifier.urihttps://hdl.handle.net/11772/22740
dc.identifier.volume354
dc.identifier.wosWOS:000651131800001
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherWiley-V C H Verlag Gmbh
dc.relation.ispartofArchiv Der Pharmazie
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzWoS_20251016
dc.subject1,3,4-Oxadiazole
dc.subjectCarbonic Anhydrase
dc.subjectCholinesterase
dc.subjectQuinoxalin
dc.subjectAlpha-Glucosidase
dc.titleNew quinoxalin-1,3,4-oxadiazole derivatives: Synthesis, characterization, in vitro biological evaluations, and molecular modeling studies
dc.typeArticle
dspace.entity.typePublication

Dosyalar